Currently, there are 1.73B common shares owned by the public and among those 1.73B shares have been available to trade.
The company’s stock has a 5-day price change of -2.17% and -7.87% over the past three months. ABT shares are trading -6.24% year to date (YTD), with the 12-month market performance down to -5.34% lower. It has a 12-month low price of $89.67 and touched a high of $121.64 over the same period. ABT has an average intraday trading volume of 5.68 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.40%, -1.57%, and -2.91% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Abbott Laboratories (NYSE: ABT) shares accounts for 77.17% of the company’s 1.73B shares outstanding.
It has a market capitalization of $179.53B and a beta (3y monthly) value of 0.72. The stock’s trailing 12-month PE ratio is 32.15, while the earnings-per-share (ttm) stands at $3.21. The company has a PEG of 3.97 and a Quick Ratio of 1.11 with the debt-to-equity ratio at 0.38. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.54% over the week and 1.70% over the month.
Earnings per share for the fiscal year are expected to increase by 4.25%, and 11.15% over the next financial year. EPS should shrink at an annualized rate of 8.10% over the next five years, compared to 19.65% over the past 5-year period.
Looking at the support for the ABT, a number of firms have released research notes about the stock. Goldman stated their Buy rating for the stock in a research note on May 30, 2024, with the firm’s price target at $121. Morgan Stanley was of a view on May 30, 2023 that the stock is Equal-Weight, while Wolfe Research gave the stock Underperform rating on April 20, 2023, issuing a price target of $107- $103. UBS on their part issued Buy rating on April 20, 2023.
